Comparative Pharmacology
Head-to-head clinical analysis: ANDRODERM versus ANDROID 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDRODERM versus ANDROID 5.
ANDRODERM vs ANDROID 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone is an androgen receptor agonist; it binds to androgen receptors, leading to changes in gene expression that promote male secondary sexual characteristics and maintain libido, muscle mass, and bone density.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Apply one 2.5 mg or 5 mg transdermal system to clean, dry, intact skin on the abdomen, upper arms, or thighs once daily, preferably in the morning. Starting dose is 5 mg daily; adjust based on serum testosterone levels.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
None Documented
None Documented
Terminal elimination half-life is approximately 10–100 minutes (rapid), but due to transdermal absorption, effective half-life is extended to about 8–10 hours after patch application.
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Approximately 90% of testosterone metabolites are excreted in urine as glucuronide and sulfate conjugates; 6% are excreted in feces via bile.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Category C
Category C
Androgen
Androgen